RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.



from The Medical News http://ift.tt/1aBbBOX